跳至主要内容
临床试验/DRKS00030403
DRKS00030403招募中不适用

An observational, non-interventional, multicenter, prospective study to explore the association of MS-related disability worsening and loss of thalamus volume - PENTAGO

jung diagnostics GmbH0 个研究点目标入组 600 人开始时间: 2022年10月13日最近更新:
适应症

试验速览

阶段
不适用
状态
招募中
发起方
入组人数
600

研究概览

简要总结

暂无简介。

研究设计

研究类型
Observational

入排标准

年龄范围
18 Years 至 55 Years(—)
性别
All

入选标准

  • ? MS, as diagnosed by the revised 2017 McDonald criteria
  • ? Exhibiting a relapsing clinical course and history of brain MRI lesions consistent with MS
  • ? Ages 18 to 55 years, inclusive
  • ? Meet one of the following disease activity criteria
  • a. more than 10 T2 lesions at the time of the first visit OR
  • b. at least one documented relapse with the last 12 months prior to the first visit OR
  • c. documented evidence of at least 1 Gd-enhancing lesion on brain MRI within the last 12 months prior to the first visit OR
  • d. documented evidence of at least one new or one enlarging T2 lesion within the last 12 months prior to the first visit.
  • ? Either receive or about to receive oral immune therapies as first or second DMT approach, such as teriflunomide, ozanimod, dimethylfumarate, ponesimod, and diroximethylfumarate.
  • ? Either receive or about to receive second line therapies, such as e.g. monoclonal antibodies, but the number of patients receiving monoclonal antibodies should be restricted to 1/3 of the overall study population.

排除标准

  • ? Primary or secondary progressive MS at time of enrollment
  • ? Patients who are not eligible to receive MRI

研究者

发起方
jung diagnostics GmbH

相似试验